No Data
No Data
Evoke Pharma Highlights GIMOTI As A Leading Solution For Gastroparesis Treatment As Domperidone Supply Ends; FDA Posts Update As Mechanism To Obtain Unapproved Domperidone Expected To Lose Supply In Early 2025
Express News | Evoke Pharma Inc: Two Patents Are Expected to Be Orange Book Listable and Expire at End of 2029
Express News | Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting Gimoti®
US Manufacturing Index Rises To 43, Highest Since 2020
Evoke Pharma GAAP EPS of -$0.94, Revenue of $2.65M
Evoke Pharma | 8-K: Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Unlock the Full List